Aurinia Pharmaceuticals Inc. (AUPH) Stock Grade

About Aurinia Pharmaceuticals Inc.'s fundamentals

Aurinia Pharmaceuticals is a biotechnology company with a $2.1 billion market cap that has achieved profitability with a remarkable 101.5% net margin, indicating it earns more than a dollar in profit for every dollar of revenue. The company is growing revenue at a 20.4% year-over-year rate while generating a 49.4% return on equity, demonstrating strong operational efficiency and shareholder value creation. Trading at a P/E ratio of 7.5, the company's valuation appears relatively modest given its profitability metrics. The company does not currently pay a dividend.